Fortis Healthcare Limited announced its audited consolidated financial results for the quarter and year ended March 31, 2026. The company reported strong financial performance with significant growth in both revenue and profitability for the full year. The board of directors recommended a final dividend of ₹1 per equity share, subject to shareholder approval. The company also disclosed that the newspaper publication of these audited financial results under Regulation 47 of SEBI (LODR) Regulations, 2015, was scheduled for May 23, 2026, in the Financial Express and Rozana Spokesman.

Consolidated Financial Performance

For the financial year 2026, Fortis Healthcare delivered robust growth. Consolidated revenue from operations increased by 17.3% to ₹9,128 Cr, compared to ₹7,783 Cr in the previous year. Profit After Tax (PAT) rose by 31.5% to ₹1,064 Cr from ₹809 Cr in FY25. Operating EBITDA for the year stood at ₹2,085 Cr, up 31.3% year-on-year, with an improved margin of 22.8% compared to 20.4% in FY25.

The table below summarises the key consolidated financial metrics for FY26:

The financial results include exceptional items. For FY26, a net exceptional loss of ₹22.2 Cr was recognised, primarily pertaining to the one-time impact of new Labour Codes, set off by a reversal of impairment in an associate company.

Quarterly Performance (Q4 FY26)

In the fourth quarter of FY26, Fortis Healthcare reported consolidated revenue of ₹2,365 Cr, a 17.8% increase from ₹2,007 Cr in Q4 FY25. Operating EBITDA grew to ₹531 Cr, with margins at 22.51% compared to 21.93% in the corresponding quarter of the previous year. Profit After Tax for Q4 FY26 stood at ₹271 Cr, up 44.2% year-on-year.

The table below presents the key Q4 financial metrics:

Segment Performance

The hospital business continued to be the primary growth driver, with revenue increasing 19.1% to ₹7,773 Cr in FY26. The segment reported an operating EBITDA of ₹1,724 Cr and a margin of 22.2%. Key operational metrics included an average revenue per occupied bed (ARPOB) of ₹2.51 Cr per annum and an occupancy rate of 68%.

The diagnostics business reported revenue of ₹1,527 Cr, an 8.5% increase over the previous year. Operating EBITDA for the segment surged 44.7% to ₹360 Cr, with margins improving to 23.6% from 17.7% in FY25.

Dividend and Corporate Developments

The board recommended a final dividend of ₹1 per equity share, equivalent to 10% of the face value of ₹10 each, subject to approval by shareholders at the Annual General Meeting. During the year, the company expanded its network through acquisitions, adding approximately 500 beds via the acquisition of People Tree Hospital in Bengaluru and Shrimann Hospital in Jalandhar. The company also entered into a long-term lease arrangement for the Greater Noida Hospital. As of March 31, 2026, Fortis Healthcare's net debt stood at ₹2,334 Cr, with a net debt to EBITDA ratio of 1.09x.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE061F01013/1cf1ee9b3f53484b.pdf

Max Healthcare Institute has received a significant regulatory development as the Competition Commission of India (CCI) has ordered the closure of an anti-competition case that had been ongoing for approximately 10 years. The case involved Max Healthcare and 12 hospitals, marking the end of a prolonged regulatory proceeding that had been active for over a decade.

CCI Orders Closure of Long-Standing Case

The Competition Commission of India, India's apex body for regulating competition-related matters, issued the order to bring the decade-old case to a close. The case had implicated Max Healthcare along with 12 hospitals, making it a notable regulatory matter within the Indian healthcare sector. The CCI's directive formally concludes the proceedings that had persisted for around 10 years.

Key Details of the Development

The following table summarises the key parameters of this regulatory development:

The closure of this case represents the conclusion of one of the longer-running anti-competition proceedings in the Indian healthcare industry. The CCI's order to end the case involving Max Healthcare and the 12 associated hospitals brings regulatory finality to a matter that had remained active for a significant period. No further details regarding the specific nature of the original allegations or the grounds for closure were available in the source data.